• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Eli Lilly (NY:LLY)

    1,222.87 -12.70 (-1.03%)
    Streaming Delayed Price Updated: 2:01 PM EDT, Jul 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Eli Lilly

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    News headline image
    The Market Just Got Shaken—These 3 ETFs May Come Out Stronger ↗
    As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities. 
    Via MarketBeat
    Topics Artificial Intelligence ETFs Stocks
    News headline image
    Stocks making big moves yesterday: Carlisle, Rivian, Blink Charging, Genpact, and Eli Lilly
    Check out the companies making headlines yesterday: Carlisle (NYSE:CSL): Building envelope solutions provider Carlisle Companies (NYSE:CSL) fell by 4.2% on T... 
    Via StockStory
    Topics Economy Electric Vehicles
    News headline image
    Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026 ↗
    Eli Lilly's next leg of growth may have less to do with how well its weight loss drugs work and more to do with how many people can finally get them. 
    Via The Motley Fool
    News headline image
    Why Eli Lilly Stock Climbed to a Record High Today ↗
    Wall Street is getting more bullish on the pharma giant's shares. 
    Via The Motley Fool
    News headline image
    Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom ↗
    Don't sleep on these medical device leaders. 
    Via The Motley Fool
    Topics Supply Chain
    News headline image
    3 Reasons to Buy Novo Nordisk Stock ↗
    The stock is down, but it isn't out yet. 
    Via The Motley Fool
    News headline image
    Why Eli Lilly (LLY) Stock Is Trading Up Today
    What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.8% in the afternoon session after JPMorgan's Chris Schott raised his pri... 
    Via StockStory
    News headline image
    U.S. Healthcare Spending Just Hit $5.7 Trillion and Continues to Grow: 2 Stocks to Buy to Profit From the Trend ↗
    Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks. 
    Via The Motley Fool
    News headline image
    Warren Buffett Has Recommended 1 Investment for Decades -- but There's a Hidden Risk Many Investors Are Overlooking ↗
    This key factor didn't exist when Buffett first gave the advice, but does that change its appeal? 
    Via The Motley Fool
    Topics Artificial Intelligence ETFs Economy
    News headline image
    Eli Lilly's Market Cap Balloons Again On This IPO's Setback ↗
    Eli Lilly shares hit a new record high Tuesday after IPO stock Kailera posted lackluster test results for its obesity drug. 
    Via Investor's Business Daily
    Topics Initial Public Offering
    News headline image
    Eli Lilly Stock Hits a New All-Time High: Has It Gotten Too Expensive to Buy? ↗
    Shares of Eli Lilly have risen by over 40% since the company last reported earnings. 
    Via The Motley Fool
    News headline image
    Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years. ↗
    The stock has surged 160% over the past three years. Meanwhile, two key drugs could continue driving rampant growth. 
    Via The Motley Fool
    News headline image
    As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner ↗
    Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near. 
    Via MarketBeat
    News headline image
    Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗
    Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion. 
    Via The Motley Fool
    News headline image
    Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years? ↗
    The weight-loss market is crowded, but this company's lead drug candidate has several key advantages. 
    Via The Motley Fool
    News headline image
    Could Buying Eli Lilly Stock Today Set You Up for Life? (Hint: Yes.) ↗
    Lilly offers investors safety and growth. 
    Via The Motley Fool
    News headline image
    IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors? ↗
    Compare the portfolio concentration, risk profiles, and long-term growth of these two pharma ETFs. 
    Via The Motley Fool
    Topics ETFs Intellectual Property
    News headline image
    Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best? ↗
    One offers broad stability with lower costs and higher income, while the other chases biotech growth with 89.3% annual returns but steeper volatility. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030? ↗
    This biotech might have a bright future, but it'll need to survive against the incumbents to do so. 
    Via The Motley Fool
    News headline image
    Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP? ↗
    Compare portfolio concentration, risk profiles, and long-term growth as these two pharma ETFs take different approaches to capturing sector opportunity. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    State Street Health Care ETF Tops Invesco Pharma on Cost and Size ↗
    Compare sector breadth, yield, and recent performance as these two healthcare ETFs take different approaches to growth and income. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Vanguard Health Care vs. iShares Biotech: How Do These ETFs Stack Up? ↗
    Broad healthcare diversification or concentrated biotech growth? Compare cost, risk, and portfolio composition to find your fit. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    FHLC vs. BBH: Which Healthcare ETF Is the Better Buy? ↗
    Compare fees, diversification, and risk between these two leading healthcare ETFs. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying ↗
    The stock is known to soar on good news. 
    Via The Motley Fool
    News headline image
    Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly? ↗
    Johnson & Johnson doesn't need GLP-1 drugs to grow, and that's good news for long-term investors. 
    Via The Motley Fool
    News headline image
    Dr. Danielle Carrera’s Beyond Better, Thrive Debuts as Amazon #1 New Release and Top 5 Bestseller
    Via Get News
    News headline image
    Here's Why Viking Therapeutics Stock Surged Higher in June ↗
    Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug. 
    Via The Motley Fool
    News headline image
    SPDR Health Care ETF Tops iShares Biotech in Long-Term Returns ↗
    Compare portfolio diversity, risk profiles, and income potential as you weigh these two leading healthcare ETFs. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China ↗
    Innovent and Eli Lilly sign a China commercialization deal for Verzenios, expanding patient access while Lilly retains manufacturing. 
    Via Benzinga
    News headline image
    $100 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today ↗
    Eli Lilly (NYSE:LLY) has outperformed the market over the past 20 years by 7.2% on an annualized basis producing an average annual return of 16.46%. Currently, Eli Lilly has a market capitalization of... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.